Trial · NCT05967442

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

NCT05967442, Phase 3, Completed, Wake Forest University Health Sciences; results first posted 2024-10-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines. Trials, record NCT05967442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05967442

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines
NCT number: NCT05967442
Status: Completed
Phases: Phase 3
Enrollment: 157 participants, actual
Lead sponsor: Wake Forest University Health Sciences
Conditions: Migraine, Headache
Interventions: Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection
First posted: 2023-08-01
Last updated: 2024-10-08
Results first posted: 2024-10-01

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	30 Minute Pain Score	30 minutes after initiation	Scores range from 0-10. A higher score, denotes more pain
Secondary	Length of Stay	From time of arrival to time of discharge.	Emergency Department Length of stay. Measured from time of arrival to time of discharged documented in the electronic medical record.
Secondary	Need for Rescue Analgesia	From time of arrival to time of discharge.	Percentage of participants who had necessity for rescue analgesics after study drug administration

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	30 Minute Pain Score	30 minutes after initiation	Full cohort	score on a scale	MEDIAN
SECONDARY	Length of Stay	From time of arrival to time of discharge.		minutes	MEDIAN
SECONDARY	Need for Rescue Analgesia	From time of arrival to time of discharge.		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
30 Minute Pain Score	Magnesium	3	Inter-Quartile Range 1 to 4	score on a scale
30 Minute Pain Score	Metoclopramide	3	Inter-Quartile Range 1 to 4	score on a scale
30 Minute Pain Score	Prochlorperazine	3	Inter-Quartile Range 1 to 5	score on a scale
Length of Stay	Magnesium	325	Inter-Quartile Range 274 to 410	minutes
Length of Stay	Metoclopramide	308	Inter-Quartile Range 263.5 to 403	minutes
Length of Stay	Prochlorperazine	332	Inter-Quartile Range 268.5 to 391	minutes
Need for Rescue Analgesia	Magnesium	26		Participants
Need for Rescue Analgesia	Metoclopramide	15		Participants
Need for Rescue Analgesia	Prochlorperazine	17		Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Magnesium	61
Overall Study	STARTED	Metoclopramide	44
Overall Study	STARTED	Prochlorperazine	52
Overall Study	COMPLETED	Magnesium	61
Overall Study	COMPLETED	Metoclopramide	44
Overall Study	COMPLETED	Prochlorperazine	52
Overall Study	NOT COMPLETED	Magnesium	0
Overall Study	NOT COMPLETED	Metoclopramide	0
Overall Study	NOT COMPLETED	Prochlorperazine	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Magnesium	61
Total, all-cause mortality	Metoclopramide	44
Total, all-cause mortality	Prochlorperazine	52
Total, other adverse events	Magnesium	61
Total, other adverse events	Metoclopramide	44
Total, other adverse events	Prochlorperazine	52
Total, serious adverse events	Magnesium	61
Total, serious adverse events	Metoclopramide	44
Total, serious adverse events	Prochlorperazine	52

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05967442

GET https://conductscience.org/api/trials/v1/NCT05967442/registered

API reference For AI assistants